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Multiple myeloma (MM) is the second most commonly diagnosed hematological malignancy, characterized by a monoclonal
proliferation of malignant cells in the bone marrow. Despite recent advances in treatment strategies, MM remains incurable
and new therapeutical targets are needed. Recently forodesine, a purine nucleoside phosphorylase inhibitor, was found to induce
apoptosis in leukemic cells of chronic lymphocytic leukemia patients by increasing the dGTP levels. We therefore tested whether
forodesine was able to inhibit proliferation and/or induce apoptosis in both murine and human MM cells through a similar
pathway. We found that after 48 hours of treatment with forodesine there was a slight dGTP increase in 5T33MM and RPMI-
8226 MM cells associated with partial inhibition of proliferation and a limited induction of apoptosis. When investigating the
pathways leading to cell cycle arrest and apoptosis, we observed an upregulation of p27, caspase 3, and BIM. We can conclude that
forodesine has some eﬀects on MM cells but not as impressive as the known eﬀects in leukemic cells. Forodesine might be however
potentiating towards other established cytotoxic drugs in MM.
1.Introduction
Multiple myeloma (MM) is the second most prevalent
hematological malignancy, accounting for 1% of all cancers.
It is characterized by expanding malignant plasma cells
in the bone marrow, secreting a monoclonal paraprotein,
and inducing angiogenesis and osteolysis. Despite recent
advances in therapy, MM still remains fatal with an average
survival of 4 years [1].
Forodesine belongs to the family of purine nucleoside
analogues (PNAs), but unlike PNAs it does not get incorpo-
rated into DNA/RNA [2]. Forodesine is a highly potent and
speciﬁc purine nucleoside phosphorylase (PNP) inhibitor,
and in the presence of dGuo, forodesine has been shown to
inhibit cell proliferation by accumulating the dGTP levels
in the cell [3]. Accumulated dGTP inhibits ribonucleotide
reductase, thus preventing the synthesis of deoxyribonucleo-
side diphosphates. Depletion of deoxynucleotides eventually
leads to cell cycle arrest [3, 4]. Accumulation of dGTPs
has also been shown to induce oxidative stress, leading to
the activation of the mitochondrial apoptotic pathway [5].
Balakrishnan et al. [6] showed that the apoptotic activity
of forodesine was mediated by phosphorylation of p53 and
activation of p21, while Alonso et al. [7] found that the
activity of forodesine is also mediated through induction of
p73andtheBH3-onlymemberoftheBcl-2family,BIM.BIM
promotes apoptosis by modulating the interactions between
theantiapoptotic andtheproapoptotic membersoftheBcl-2
family [8].
Forodesine has been shown to induce apoptosis in
vitro in several malignant T-cell lines, such as T-cell acute
lymphoblastic leukemia (T-ALL) [5], and B-cell lines, such
asB-cellacutelymphoblasticleukemia[9]andB-cellchronic
lymphocytic leukemia (B-CLL) [6, 7]. Furthermore, it is2 Advances in Hematology
currently being tested in phase I/II clinical trials for patients
with these malignancies [10–15]. It has been reported [6]
that the eﬃcacy of forodesine is partially dependent on the
levels of deoxycytidine kinase (dCK) in the cells. dCK is the
primary enzyme for the conversion of dGuo to dGMP, which
is then converted to dGTP. As T cells have high levels of dCK,
they form an attractive target for a PNP inhibitor.
To our knowledge, despite being a hematological malig-
nancy, the eﬀect of forodesine on MM cells has not yet
been investigated. Some studies have tested the potency
of the ﬁrst PNAs in MM [16]. Namely, Kraut et al. [17]
found that ﬂudarabine, a nucleoside analogue of adenine,
alone did not have any antimyeloma activity nor did 2-
chlorodeoxyadenosine alone [18]. However, Bj¨ orkstrand
et al. [19] reported that in a phase II study, ﬂudarabine
increased the reduction of MM tumor cells when added to
the VAD regimen (vincristine, dexamethasone, and doxoru-
bicin).
Asforodesineismorepotentthantheﬁrst-linePNAsand
blocksproliferationthroughadiﬀerentpathway,wetestedits
activityinMMcellsinvitro.Forthisweusedboththemurine
5T33MM cells as well as the human RPMI-8226 cells. The
5T33MM model is an in vivo murine model that resembles
thehumandiseaseclosely,withdevelopmentofangiogenesis.
Of this model, an in vitro line has been developed which can
grow stroma independently [20].
We examined the eﬀects of forodesine on the dGTP
levels as well as proliferation and apoptosis of the MM
cells, compared to a T-ALL line, the MOLT-4 line. We also
investigated the signaling pathways which lead to apoptosis
and cell cycle arrest.
2.MaterialandMethods
2.1. 5T33MM Model. C57BL/KaLwRij mice were purchased
from Harlan (Horst, The Netherlands) and used at 6 to 10
weeks of age. They were housed and maintained following
the conditions approved by the Ethical Committee for
Animal Experiments, VUB (license no. LA1230281). The
animal ethics meet the standards required by the UKCCCR
Guidelines (UKCCCR, 1998).
The 5T33MMvv cells were isolated from the BM as
previously described [21]. The BM cells were suspended in
supplemented serum-free medium (RPMI 1640 (GIBCO,
Life Technologies, Ghent, Belgium). The 5T33MM cells with
>95% viability were enriched by Lympholyte M (Cedarlane,
Hornby, Canada) gradient centrifugation at 1000g for 20
minutes and reached >80% purity (assessed by staining with
anti-idiotype antibodies).
2.2. Cell Lines. The murine 5T33MM (MM) [20], human
RPMI-8226 (MM) [22], and human MOLT-4 (T-ALL) [23]
cells were maintained in RPMI-1640 medium supplemented
with 10% FCS (Fetal Clone I, Hyclone, Logan, UT).
2.3. Reagents. Forodesine (BCX-1777) was provided by
Mundipharma Research Ltd., Cambridge, England, and
dGuo obtained from Sigma-Aldrich (Munich, Germany).
2.4. dGTP Assay. The dGTP assay was performed according
to the protocol by Bantia et al. [4]. Brieﬂy, dGTPs from 5
× 106 treated cells were extracted in methanol and dried
by a TurboVap (Rotational Vacuum Concentration RVC-
2-25, Harz, Germany). Primers for dGTP (5 -TTTCTT-
TCTTTCTTTCTTTCGGCGGTGGAGGCGG-3 ;3  -CCG-
CCACCTCCGCC-5 ) were annealed and added, together
with Klenow polymerase and 3H-ATP (Vitrax, CA, USA).
After 30 min incubation at 37◦C, cells were harvested on
DE81 paper, and radioactivity was detected with a 1450
Microbeta Liquid Scintillation Counter (Wallac, Finland).
Values were correlated to a known dGTP standard curve
(Sigma-Aldrich).
2.5. BrdU Assay. BrdU (Sigma-Aldrich) was added to the
cultures in vitro 2 hours before analysis. Cells were then
ﬁxed, permeabilized, and then stained with a FITC-anti-
BrdU antibody (Roche Diagnostics, Manheim, Germany) as
performed previously [24]. Flow cytometry was performed
using a FACS Canto and the FACSDiva software (BD
Pharmingen, Erembodegem, Belgium).
2.6. Annexin V/7-AAD Assay. After treatment, cells were
washed and incubated with annexin V and 7-AAD (BD
Pharmingen) for 15 minutes, followed by ﬂow cytometric
analysis (FACS Canto).
2.7. Western Blot. Cell lysates were collected as described
previously [25], run over an SDS-PAGE electrophoresis, and
blotted on PVDF membrane. The following antibodies were
used: dCK (ab83046), Mcl-1 (ab32087) (abcam, Cambridge,
UK), BIM (#2819), caspase 3 (#9665), α-tubulin (#2144), β-
actin (#4967) (Cell Signaling Technology, MA, USA), c-myc
(sc 764), and p27 (sc 528, Santa Cruz, CA, USA).
2.8. Statistical Analysis. To determine statistical signiﬁcance,
the Mann-Whitney test was used. P values <.05 were
considered signiﬁcant.
3. Results and Discussion
As the level of dCK is supposed to be a limiting factor for the
activity of forodesine, we ﬁrst examined the level of dCK in
severalMMcelllines.AscanbeseeninFigure 1,allMMlines
express dCK, especially the 5T33MM, MMS1, and RPMI-
8226cells.Therefore,wedecidedtouse5T33MMandRPMI-
8226 cells for further experiments.
We next investigated the eﬀects of forodesine on the
dGTP levels in the MM cells since the eﬀect of forodesine
is mediated by increased dGTP levels. We added an external
source of dGuo to mimic in vivo plasma elevation of dGuo
levels [6]. As it has been shown that the eﬀects of forodesine
depend on the concentration of dGuo [7], we ﬁrst examined
the eﬀects of 5μM forodesine with diﬀerent concentrations
of dGuo on the dGTP levels in 5T33MM cells compared to
MOLT-4 cells. We found that after 24 hours only limited
eﬀect could be seen (Figures 2(a) and 2(b)), but after
48 hours there was a two-fold increase in dGTP levelsAdvances in Hematology 3
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Figure 1: Expression of deoxycytidine kinase (dCK) in MM cells. With Western blot, the level of dCK was determined in several MM cell
lines and compared to MOLT-4 cells-(1): Karpas, (2): LP-1, (3): MMS-1, (4): RPMI-8226, (5): 5T33MM, (6): 5T33MMvv, and (7): MOLT-4.
β-actin was used as loading control; one experiment representing 3 is shown.
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Figure 2: Eﬀect of forodesine on dGTP levels in MM cells. The relative amount of dGTP was determined in MOLT-4 and 5T33MM cells,
treated with 5μM forodesine and 10, 20, or 30μM dGuo at 24 hours (a, b) and 48 hours (c, d). The mean value + SD is shown of 3
independent experiments; ∗P<. 05 compared to CT, CT = control and FD = forodesine.
in the MOLT-4 cells (Figure 2(c)) and a 30% increase in
the 5T33MM cells (Figure 2(d)). dGuo alone also gave an
increase in dGTP levels, and this is in line with Balakrishnan
et al. [6] who also found that dGuo alone could increase
dGTP levels in some patient samples. In contrast, they
already found a dGTP increase after 4 hours of treatment in
CLL cells. This could be due to a diﬀerence in methods or a
diﬀerence in cells examined.
As we observed some increase in dGTP levels in the MM
cells we continued to examine the eﬀects of forodesine on
the proliferation and apoptosis of the cells. We now used
diﬀerentconcentrationsof forodesine together withdiﬀerent
concentrations of dGuo for 24 and 48 hours. At 24 hours
we saw some reduction in BrdU uptake in both MOLT-4
(Figure 3(a)) and RPMI-8226 (Figure 3(c)) cells (up to 40%
reduction) but not in the 5T33MM cells(Figure 3(b)). When
looking at the eﬀects at 48 hours, we found a complete block
in proliferation in the MOLT-4 cells (Figure 3(d)) and 15%
reduction in the 5T33MM cells (Figure 3(e)). Examination
of the number of apoptotic cells revealed that forodesine had
no eﬀect on the MM cells at 24 hours (Figures 4(b) and
4(c)), while it did reduce the percentage of living cells in the
MOLT-4 cells with 40% (Figure 4(a)). At 48 hours we saw
in the MOLT-4 cells a pronounced dose-dependent decrease
of the living cells when treated with diﬀerent concentrations
of dGuo, while the concentration of forodesine made no
diﬀerence (Figure 4(d)). Here also a decrease in living cells
c o u l db es e e nw h e n2 0 μMa n d3 0 μMd G u ow e r ea d d e d
alone, correlating to the observed increase in dGTP levels.
In the MM cells we observed no (5T33MM) or small4 Advances in Hematology
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Figure 3: Eﬀect of forodesine on proliferation of MM cells. The relative amount of BrdU uptake is shown in MOLT-4, 5T33MM, and RPMI-
8226 cells treated with diﬀerent concentrations of forodesine and dGuo at 24 hours (a, b, c) and 48 hours (d, e, f). The mean value + SD is
shown of 3 independent experiments; ∗P<. 05 compared to CT, CT = control, and FD = forodesine.
(10%, RPMI-8226) eﬀect of forodesine treatment (Figures
4(e) and 4(f)). When the 5T33MMvv cells were treated ex
vivo with forodesine, we also found a limited eﬀect (up to
20%, data not shown).
We ﬁnally examined some molecular targets of forode-
sine in the proliferative and apoptotic pathways. To our
knowledge the eﬀects of forodesine on the diﬀerent cell
cycle proteins has not yet been extensively investigated. We
treated 5T33MM cells for 48 hours with forodesine and
MOLT-4 cells for 24 hours, so we could observe the initial
eﬀects of forodesine. We found that while forodesine had
no eﬀect on cell cycle stimulators such as cyclin D2 (data
not shown) or c-myc, we did ﬁnd an increase in the levels
of p27, a cyclin-dependent kinase inhibitor (CKI) in both
MOLT-4 cells (Figure 5(a)) as 5T33MM (5(b)), indicating
that proliferation reduction is mediated by increased cell
cycle inhibition. This is in line with Balakrishnan et al. [6]
who found an increase in p21 in CLL cells after treatment
with forodesine. Both p21 and p27 belong to the CIP/Kip
family of CKIs and play a role in inhibiting all cyclins (D,
E, A, and B) and Cdks (4, 6, and 2), thus inducing cell cycle
arrest [26].
When examining the eﬀects of forodesine on the apop-
totic pathway, we saw a clear activation of caspase 3, the
eﬀector caspase in the apoptotic pathway, in the MOLT-4
cells (Figure 6(a)), and also to a lesser extent in the 5T33MM
cells (6(b)). Caspase 3 can be activated through the intrinsic
or extrinsic pathway, with the intrinsic pathway initiated by
the BH3-only proteins. A balance between the antiapoptotic
members of the Bcl-2 family and the proapoptotic mem-
bers controls the outcome of the mitochondrial apoptotic
pathway [27]. Alonso et al. [7] have found that apoptosis
inducedby forodesinein CLL cellsismediated by anincrease
in proapoptotic BIM and a reduction in antiapoptotic Mcl-
1, creating an imbalance in the Bcl-2 family and rendering
the cells more sensitive to the proapoptotic members. We
detected the same eﬀects in the 5T33MM cells (Figure 6(b));
however, we could not see an increase in BIM expression in
the MOLT-4 cells (6(a)). This discrepancy could be due to
the diﬀerence in cell lineage.
From these data it is evident that, despite having high
levels of dCK, forodesine is more eﬀective in leukemic
cells than in myeloma cells. Kicska et al. [3] have also
stated that dCK activity alone is insuﬃcient to predict
forodesine susceptibility. They postulated that cells resistant
to anti-PNP agents may not accumulate enough dGTP to be
eﬀective because of decreased dGuo uptake and/or increased
dGMP phosphatase activity. Huang et al. [28] stated that
nucleoside transporters also play a critical role in the cellular
transport of nucleoside analogues. They found that the
equilibrative nucleoside transporters ENT1 and ENT2 were
necessary for forodesine uptake and that dGuo uptake
was primarily dependent on the concentrative nucleoside
transports (CNTs). It could be possible that one of these is
not eﬃcient in MM cells.
Despite having limited therapeutical value in MM as a
single agent, it is possible that forodesine could increase
the eﬀect of other cytotoxic therapeutics. One possibleAdvances in Hematology 5
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Figure 4: Eﬀe c to ff o r o d e s i n eo na p o p t o s i so fM Mc e l l s . The % live, early apoptotic, late apoptotic, and dead cells are shown for MOLT-4,
5T33MM, and RPMI-8226 cells, treated with diﬀerent concentrations of forodesine and dGuo at 24 hours (a, b, c) and 48 hours (d, e, f).
The mean value is shown of 3 independent experiments; ∗P<. 05 compared to CT, CT = control, and FD = forodesine.
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drug that might work synergistically with forodesine is
the demethylation inhibitor, decitabine, as this drug also
becomes activated through phosphorylation by dCK. If
forodesine could potentiate the eﬀect of existing drugs in
MM, it might be beneﬁcial to examine its eﬀect preclinically
in combination studies.
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